|
|
Last Modified: 6/1/2002  First Published: 4/1/2002 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
MGI-IROF-003 UARIZ-HSC-00305, NCT00033735
|
|
|
|
|
|
|
|
Last Modified: 8/27/2003  First Published: 3/1/2001 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
NABTT-2005 JHOC-NABTT-2005, NCT00012038, NABTT-2005
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
IROF-017 NCT00374660
|
|
|
|
|
|
|
|
Last Modified: 5/1/2000  First Published: 8/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
MSKCC-98009 MSKCC-98007, NCI-T97-0119, NCT00003390, T97-0119
|
|
|
|
|
|
|
|
Last Modified: 4/1/2000  First Published: 9/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
MDA-DM-97308 NCI-T97-0113, NCT00003441, T97-0113
|
|
|
|
|
|
|
|
Last Modified: 6/14/2006  First Published: 10/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
Not specified
|
|
|
|
NCI
|
|
|
|
VU-VCC-THO-9817 NCI-T97-0106, T97-0106
|
|
|
|
|
|
|
|
Last Modified: 1/1/2002  First Published: 12/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
NCI-98-C-0162 MB-403, NCI-T98-0030, NCT00019552, T98-0030
|
|
|
|
|
|
|
|
Last Modified: 5/4/2005  First Published: 1/1/1999 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
CLB-39805 NCT00003666, CALGB-39805
|
|
|
|
|
|
|
|
Last Modified: 7/1/2000  First Published: 4/1/1999 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
UTHSC-9895011082 MGI-114.27.P98-03, SACI-IDD-98-18, NCI-V99-1517, NCT00003760
|
|
|
|
|
|
|
|
Last Modified: 4/26/2007  First Published: 4/1/1999 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
MDA-DM-98221 NCI-T98-0071, T98-0071
|
|
|
|